Tominersen is a Antisense Oligonucleotide owned by F. Hoffmann-La Roche, and is involved in 6 clinical trials, of which 4 were completed, and 2 are ongoing.

Tominersen (RG-6042) is a Huntingtin protein inhibitor. Mutations in the HTT (Huntingtin) gene causes Huntington disease. The HTT gene provides instructions for making Huntingtin protein. The drug candidate blocks the production of all forms of Huntingtin protein responsible for Huntington disease.

The revenue for Tominersen is expected to reach a total of $2.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tominersen NPV Report.

Tominersen was originated by Ionis Pharmaceuticals and is currently owned by F. Hoffmann-La Roche.

Tominersen Overview

Tominersen (RG-6042) is under development for the treatment of Huntington's disease. The drug candidate is administered through intrathecal route. It is a chimeric 2'-O-(2-methoxyethyl) modified oligonucleotide targeted to huntingtin RNA. It is based on antisense technology and brain shuttle technology. It is a new molecular entity (NME) and acts by targeting HTT.

F. Hoffmann-La Roche Overview

F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, commercial laboratories, healthcare professionals, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF62,801 million for the fiscal year ended December 2021 (FY2021), an increase of 7.7% over FY2020. In FY2021, the company’s operating margin was 28.9%, compared to an operating margin of 31.8% in FY2020. In FY2021, the company recorded a net margin of 22.2%, compared to a net margin of 24.5% in FY2020.

Quick View – Tominersen

Report Segments
  • Innovator
Drug Name
  • Tominersen
Administration Pathway
  • Intrathecal
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.